APA   Click to copy
Roviello, G., Generali, D., & Sobhani, N. (2019). The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer-a commentary on the E5103 randomized phase III clinical study. Translational Cancer Research, 8(Suppl 2 ), S94–S96. https://doi.org/10.21037/tcr.2018.10.17

Chicago/Turabian   Click to copy
Roviello, Giandomenico, Daniele Generali, and Navid Sobhani. “The Combination of Bevacizumab with Chemotherapy Is More Beneficial in the Metastatic Setting Rather than in the Adjuvant Setting for the Treatment of HER2-Negative Breast Cancer-a Commentary on the E5103 Randomized Phase III Clinical Study.” Translational Cancer Research 8, no. Suppl 2 (2019): S94–S96.

MLA   Click to copy
Roviello, Giandomenico, et al. “The Combination of Bevacizumab with Chemotherapy Is More Beneficial in the Metastatic Setting Rather than in the Adjuvant Setting for the Treatment of HER2-Negative Breast Cancer-a Commentary on the E5103 Randomized Phase III Clinical Study.” Translational Cancer Research, vol. 8, no. Suppl 2 , 2019, pp. S94–S96, doi:10.21037/tcr.2018.10.17.

@article{giandomenico2019a,
  title = {The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer-a commentary on the E5103 randomized phase III clinical study},
  year = {2019},
  issue = {Suppl 2 },
  journal = {Translational Cancer Research},
  pages = {S94-S96},
  volume = {8},
  doi = {10.21037/tcr.2018.10.17},
  author = {Roviello, Giandomenico and Generali, Daniele and Sobhani, Navid}
}